Legal & General Group Plc Boosts Stock Holdings in Astera Labs, Inc. $ALAB

Legal & General Group Plc raised its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 87.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 533,072 shares of the company’s stock after purchasing an additional 248,122 shares during the period. Legal & General Group Plc’s holdings in Astera Labs were worth $88,682,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Swedbank AB increased its stake in shares of Astera Labs by 76.8% in the fourth quarter. Swedbank AB now owns 78,140 shares of the company’s stock worth $12,999,000 after purchasing an additional 33,940 shares in the last quarter. Darden Wealth Group Inc purchased a new position in shares of Astera Labs in the fourth quarter worth about $295,000. Berkshire Capital Holdings Inc. increased its stake in shares of Astera Labs by 879,200.0% in the fourth quarter. Berkshire Capital Holdings Inc. now owns 87,930 shares of the company’s stock worth $14,628,000 after purchasing an additional 87,920 shares in the last quarter. Americana Partners LLC purchased a new position in shares of Astera Labs in the fourth quarter worth about $222,000. Finally, Legato Capital Management LLC increased its stake in shares of Astera Labs by 16.2% in the fourth quarter. Legato Capital Management LLC now owns 7,047 shares of the company’s stock worth $1,172,000 after purchasing an additional 982 shares in the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Activity at Astera Labs

In related news, COO Sanjay Gajendra sold 400,000 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $290.30, for a total transaction of $116,120,000.00. Following the completion of the transaction, the chief operating officer owned 5,064,213 shares of the company’s stock, valued at approximately $1,470,141,033.90. The trade was a 7.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Manuel Alba sold 183,000 shares of Astera Labs stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $107.61, for a total transaction of $19,692,630.00. Following the sale, the director owned 319,863 shares of the company’s stock, valued at approximately $34,420,457.43. The trade was a 36.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 2,316,257 shares of company stock valued at $474,860,636. Corporate insiders own 12.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Susquehanna lifted their target price on shares of Astera Labs from $155.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Northland Securities downgraded shares of Astera Labs from an “outperform” rating to a “market perform” rating in a research note on Tuesday. UBS Group assumed coverage on shares of Astera Labs in a research note on Tuesday, April 21st. They issued a “neutral” rating and a $180.00 target price for the company. Morgan Stanley lifted their target price on shares of Astera Labs from $210.00 to $240.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Needham & Company LLC boosted their price objective on shares of Astera Labs from $220.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Twelve research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $233.75.

Astera Labs Trading Down 1.8%

Shares of NASDAQ:ALAB opened at $343.05 on Friday. The company has a 50 day moving average of $190.82 and a 200 day moving average of $165.12. The stock has a market cap of $58.80 billion, a P/E ratio of 231.79, a P/E/G ratio of 4.62 and a beta of 3.35. Astera Labs, Inc. has a 12 month low of $84.78 and a 12 month high of $354.53.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.54 by $0.07. The company had revenue of $308.36 million during the quarter, compared to analysts’ expectations of $292.19 million. Astera Labs had a net margin of 26.72% and a return on equity of 18.49%. Astera Labs’s revenue for the quarter was up 93.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.33 earnings per share. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. On average, equities analysts forecast that Astera Labs, Inc. will post 1.84 earnings per share for the current fiscal year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.